This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
New data from a mid-stage study of an Amgen obesity drug showed that it helped participants lose a substantial amount of weight, but questions about how competitive it could be appear to be shaping the response to the news, with the company’s share price falling on the announcement. Amgen said Tuesday that that its drug, MariTide , led to an average of roughly 20% weight loss over a year in the Phase 2 study in participants who had obesity or who were overweight without type 2 diabe
Glucagon-like peptide-1 (GLP-1) receptor agonists have shown to provide meaningful benefits in chronic kidney disease (CKD) and individuals with and without diabetes. This based on the largest, most comprehensive analysis of GLP-1 antagonists on kidney and cardiovascular outcomes. While GLP-1 receptor agonists have shown benefit for type 2 diabetes, obesity and cardiovascular disease, its impact as a treatment in chronic kidney disease is not as clear, the researchers explained.
Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, talks about the best ways pharmacists can stay updated on advancements in diabetes medications and treatments.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
When you’re sick with a viral infection, you expect to feel poorly for a few days. COVID is no exception. Whether you’re hit with respiratory, GI, or flu-like symptoms such as muscle pain, headache, and fatigue, testing positive for COVID means being down for the count for a bit before returning to your daily routine. However, what if you don’t bounce back, even after you’re technically recovered?
When you’re sick with a viral infection, you expect to feel poorly for a few days. COVID is no exception. Whether you’re hit with respiratory, GI, or flu-like symptoms such as muscle pain, headache, and fatigue, testing positive for COVID means being down for the count for a bit before returning to your daily routine. However, what if you don’t bounce back, even after you’re technically recovered?
Pharmacy cash flow is still struggling even though the DIR Fee Apocalypse is over. Read on to get 7 practical tips to improve your pharmacy’s cash flow. Pharmacy cash flow is the heartbeat of your business—it keeps the lights on, the shelves stocked, and your team paid. However, in today’s pharmacy landscape, cash flow challenges are more pressing than ever.
Mount Sinai Health System has opened the doors of its new AI research center in Manhattan, the Hamilton and Amabel James Center for AI and Human Health. | Mount Sinai Health System announced on Tuesday that it opened its Hamilton and Amabel James Center for Artificial Intelligence and Human Health, which will be a research site for AI development.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Recursion Pharmaceuticals, one of the most advanced companies using artificial intelligence and machine learning tools to expedite drug development , laid off employees after closing a merger last week.
Pharmacists play a vital role in multidisciplinary health care teams by enhancing medication safety, optimizing therapeutic outcomes, expanding medication access, reducing costs, and improving patient education.
The Centers for Medicare & Medicaid Services (CMS) finalized a six-year mandatory model to increase access to kidney transplants, the agency announced Nov. 26. | CMS made some concessions to hospitals who strongly criticized the kidney transplant model proposed rule in May.
Discover the revolutionary impact of generative artificial intelligence (GenAI) on drug safety in pharmacovigilance. Learn how this cutting-edge technology is transforming the industry.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
The Centers for Medicare & Medicaid Services (CMS) is attempting to cover anti-obesity medications under Medicare Part D and Medicaid, the agency announced Nov. 26. | With time running out before leaving office, the Biden administration is proposing a rule to have Medicare and Medicaid cover anti-obesity medications and bolster guardrails for AI, among the changes.
Moderna's missteps serve as a reminder of the importance of regulatory bodies like PMCPA in upholding ethics within the pharmaceutical industry. Learn more about their role and impact.
Providers are rapidly adopting generative AI-based clinical documentation tools to aid clinicians and make digital paperwork more efficient. | Cambridge Health Alliance, the only public academic health system in Massachusetts, is deploying Abridge's AI-based medical note-taking tool across its 600 clinicians after a successful pilot.
The new class of GLP-1 weight loss drugs have been blockbusters since they arrived on the market a few years ago. These medications have made tens of billions of dollars for drugmakers and have made their way into the public consciousness in a remarkable way.
Almost three-quarters of adults in the U.S. are overweight or obese, and obesity can lead to a litany of health complications, including heart disease, joint pain, and cancer.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Happy Tuesday! Adam Feuerstein, here, filling in for your regular Readout correspondents.
Pittsburgh-based health insurer and provider Highmark Health has brought in $529 million in net income through the first three quarters of the year, according to its latest financial details releas | Highmark Health has brought in $529 million in net income through the first three quarters of the year, according to its latest financial details.
Providence was on track for its first positive operating year since the pandemic through the first six months of 2024, but a $208 million operating loss in the third quarter dragged down its perfor | Providence was on track for its first positive operating year since the pandemic through the first six months of 2024, but a $208 million operating loss in the third quarter dragged down its performance.
In 2001, a Time Magazine cover story touted Novartis’ targeted leukemia treatment Gleevec (imatinib) as a new kind of “am | Shorla Oncology has scored an FDA approval for its strawberry-flavored drink version of Novartis' cancer drug Gleevec. Dubbed Imkeldi, it becomes the first oral liquid form of imatinib.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
135 
Let's personalize your content